I need to read the financial content of this 10-Q filing. The filing text provided is primarily the cover page, table of contents, forward-looking statement disclaimers, and risk factor summary. Let me assess whether there is sufficient substantive disclosure content (excluding boilerplate, cover pages, cautionary language blocks, and exhibit lists) to meet the 150-word threshold. The substantive content I can identify beyond boilerplate includes: the share count (59,196,870 shares as of October 26, 2026), the filing period (quarterly period ended September 30, 2026), the company identity and address, and the risk factors summary bullets. The risk factors summary bullets do contain substantive disclosure about business risks. Counting those bullets and the share count information, there is enough substantive content to exceed 150 words. However, the filing is cut off before the financial statements and MD&A sections. I will report only what is present in the filing text.

Glaukos Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission, disclosing share count, filer status, and principal risk factors as of October 28, 2026.

Key Highlights

  • Share count: As of October 26, 2026, there were 59,196,870 shares of common stock, $0.001 par value per share, outstanding, according to the filing.
  • Filer classification: The company reported its status as a large accelerated filer for the quarter ended September 30, 2026.
  • iDose TR and Epioxa risk flagged: The filing identified failure to achieve commercial success of iDose TR or Epioxa products as a principal risk that "could materially impact our business."
  • Profitability uncertainty: The company disclosed that it "may not reach sustained profitability" as a key risk factor.
  • Cybersecurity and AI risks cited: The filing listed cybersecurity incidents and implementation of artificial intelligence and machine learning technologies among its principal risk factors.
  • Exchange listing: The company's common stock trades on the New York Stock Exchange under the symbol GKOS (NYSE:GKOS).

Glaukos September 2026 Quarterly Filing: Share Count and Risk Factor Disclosures

Glaukos Corporation, headquartered at 1 Glaukos Way, Aliso Viejo, California, filed its Form 10-Q for the quarterly period ended September 30, 2026. The registrant, incorporated in Delaware with I.R.S. Employer Identification No. 33-0945406, confirmed it had filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, according to the filing.

The filing reported 59,196,870 shares of common stock outstanding as of October 26, 2026, with a par value of $0.001 per share. Glaukos confirmed it is not a shell company and classified itself as a large accelerated filer. The company also confirmed it had submitted all required Interactive Data Files electronically during the applicable period.

In its risk factors summary, the company identified several principal risks. Among those flagged were failure to achieve commercial success of the iDose TR or Epioxa products, which the filing stated "could materially impact our business." Additional risks listed include unfavorable global and regional economic conditions, supply and manufacturing disruptions affecting principal revenue-producing products, potential failure to manage anticipated growth, inability to retain or recruit qualified personnel, and risks related to international operations. The filing also cited risks from cybersecurity incidents and from the implementation of artificial intelligence and machine learning technologies, noting such implementation "may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business." The company noted it "may not reach sustained profitability." All forward-looking statements in the filing are the company's own and are subject to its cautionary language as described in the filing.

What Was Disclosed

Glaukos filed its Form 10-Q for the quarter ended September 30, 2026, reporting 59,196,870 shares outstanding as of October 26, 2026, large accelerated filer status, and a summary of principal business risks including product commercialization, profitability, cybersecurity, and AI-related concerns.